Logo

Decode Q2 Loss Up 38 Percent on Revenue Decline, Higher R&D Costs

Aug 09, 2006
NEW YORK (GenomeWeb News) – Decode Genetics said today that second-quarter losses widened 38 percent on falling revenue and soaring research and development costs.
 
Receipts for the three months ended June 30 dropped 9 percent to $10.4 million from $11.4 million in the same quarter last year.
 
The company spent about $13.2 million on R&D in the second quarter, up 20 percent from $11 million in the comparable period last year. The increased costs are associated with Decode’s lead drug-discovery and -development programs, the firm said in a statement.
 
Decode said net loss for the second quarter increased to $18 million from $13 million in Q2 2005. The company attributed the loss to higher R&D costs.
 
As of June 30, Decode had approximately $115.5 million in cash and short-term investments.

Breaking News
The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.